red yeast rice，RYR

Phase 1Small molecule

red yeast rice，RYR is one of 37 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycystic Ovary SyndromeActive, not recruiting

Polycystic Ovary SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

175 competitors in Polycystic Ovary Syndrome

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Phase 3

1 2

Glucophage

Boehringer Ingelheim

Phase 3

2 3

Clomid

Ferring

Preclinical

13 4

Precose

Bayer

Preclinical

2 5

Proglycem

Teva

Preclinical

1 6

Clomid

EMD Serono

Preclinical

3 7

Cetrotide

EMD Serono

Preclinical

3 8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Tricor

JJagotec

Preclinical

1 10

Casodex

IIstituto Clinico Humanitas

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Polycystic Ovary Syndrome

NCT07106996

Clinical

Trials by Indication[1]

Polycystic Ovary Syndrome1 trial

Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycystic Ovary Syndrome

Recruiting·SSichuan Provincial People's Hospital·Phase 1·NCT07106996·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for red yeast rice，RYR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — red yeast rice，RYR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for red yeast rice，RYR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Provincial People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSichuan Provincial People's Hospital

red yeast rice，RYR

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Polycystic Ovary Syndrome1 trial

References

Drug Info

Quick Facts

Related News